Welcome to CREANT!

CREANT is the acronym of the Center for Radiopharmaceuticals Antwerp.

What we do

We create innovative radiopharmaceutical solutions that will improve the lives of cancer patients around the globe.

Discover our research

Our mission

CREANT’s mission is to ensure that the right cancer treatment is given to the right patient at the right time. By developing radiopharmaceuticals that target specific cancer markers we aim to provide an individually tailored therapeutic intervention.

Meet the team

CREANT is driven by the enthousiasm of a large number of people.

Meet the team

 

Creating innovative radiopharmaceuticals for tomorrow’s theranostics.

News

Doctoral scholarship holder in molecular imaging response to CAR T-cell therapies in multiple myeloma

The Center for Radiopharmaceuticals Antwerp (CREANT), is part of a research project together with the Laboratory of Experimental Hematology, and is looking for a doctoral scholarship holder in molecular imaging response to CAR T-cell therapies in multiple myeloma.

READ MORE

PhD defence Jonatan Dewulf

On November 3, 2022, Jonatan Dewulf, a member of CREANT, has defended his PhD thesis entitled: ‘Elucidating the tumor microenvironment: immuno-PET imaging of RANKL and CD70’ Congratulations Jonatan!

READ MORE

Publication

Our team has developed a novel immuno-PET imaging tool that can help tailoring cancer therapies. Check out our latest publication.

READ MORE

Our partners

University of Antwerp
Molecular Imaging Center Antwerp (MICA)
Antwerp University Hospital (UZA)